Publications

Found 220 results
Title [ Type(Asc)] Year
Journal Article
Mohammad DH, Yaffe MB. Fixin' to divide. Mol Cell. 2012;45(3):273-5.
Ng CW, Yildirim F, Yap YS, Dalin S, Matthews BJ, Velez PJ, Labadorf A, Housman DE, Fraenkel E. Extensive changes in DNA methylation are associated with expression of mutant huntingtin. Proc Natl Acad Sci U S A. 2013;110(6):2354-9.
Machado D, Costa RS, Ferreira EC, Rocha I, Tidor B. Exploring the gap between dynamic and constraint-based models of metabolism. Metab Eng. 2012;14(2):112-9.
Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle. 2009;8(19):3112-9.
Carlson SM, White FM. Expanding applications of chemical genetics in signal transduction. Cell Cycle. 2012;11(10):1903-9.
de Picciotto S, Imperiali B, Griffith LG, K Wittrup D. Equilibrium and dynamic design principles for binding molecules engineered for reagentless biosensors. Anal Biochem. 2014;460:9-15.
Kim H-D, Guo TW, Wu AP, Wells A, Gertler FB, Lauffenburger DA. Epidermal growth factor-induced enhancement of glioblastoma cell migration in 3D arises from an intrinsic increase in speed but an extrinsic matrix- and proteolysis-dependent increase in persistence. Mol Biol Cell. 2008;19(10):4249-59.
Wille L, Kemp ML, Sandy P, Lewis CL, Lauffenburger DA. Epi-allelic Erk1 and Erk2 knockdown series for quantitative analysis of T cell Erk regulation and IL-2 production. Mol Immunol. 2007;44(12):3085-91.
Chen C-H, Sarkar A, Song Y-A, Miller MA, Kim SJ, Griffith LG, Lauffenburger DA, Han J. Enhancing protease activity assay in droplet-based microfluidics using a biomolecule concentrator. J Am Chem Soc. 2011;133(27):10368-71.
Hori Y, Stern PJ, Hynes RO, Irvine DJ. Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy. Biomaterials. 2009;30(35):6757-67.
Bryson BD, Del Rosario AM, Gootenberg JS, Yaffe MB, White FM. Engineered bromodomains to explore the acetylproteome. Proteomics. 2015;15(9):1470-5.
Jay SM, Murthy AC, Hawkins JF, Wortzel JR, Steinhauser ML, Alvarez LM, Gannon J, Macrae CA, Griffith LG, Lee RT. An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential. Circulation. 2013;128(2):152-61.
Jay SM, Kurtagic E, Alvarez LM, de Picciotto S, Sanchez E, Hawkins JF, Prince RN, Guerrero Y, Treasure CL, Lee RT, Griffith LG. Engineered bivalent ligands to bias ErbB receptor-mediated signaling and phenotypes. J Biol Chem. 2011;286(31):27729-40.
Barzik M, McClain LM, Gupton SL, Gertler FB. Ena/VASP regulates mDia2-initiated filopodial length, dynamics, and function. Mol Biol Cell. 2014;25(17):2604-19.
Shapiro IM, Cheng AW, Flytzanis NC, Balsamo M, Condeelis JS, Oktay MH, Burge CB, Gertler FB. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet. 2011;7(8):e1002218.
Gosline SJC, Gurtan AM, JnBaptiste CK, Bosson A, Milani P, Dalin S, Matthews BJ, Yap YS, Sharp PA, Fraenkel E. Elucidating MicroRNA Regulatory Networks Using Transcriptional, Post-transcriptional, and Histone Modification Measurements. Cell Rep. 2016;14(2):310-9.
Pines G, Huang PH, Zwang Y, White FM, Yarden Y. EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism. Oncogene. 2010;29(43):5850-60.
Joslin EJ, Opresko LK, Wells A, Wiley HS, Lauffenburger DA. EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation. J Cell Sci. 2007;120(Pt 20):3688-99.
Hagen DR, Tidor B. Efficient Bayesian estimates for discrimination among topologically different systems biology models. Mol Biosyst. 2015;11(2):574-84.
Wolf-Yadlin A, Kumar N, Zhang Y, Hautaniemi S, Zaman M, Kim H-D, Grantcharova V, Lauffenburger DA, White FM. Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol. 2006;2:54.
Reddy RJ, Gajadhar AS, Swenson EJ, Rothenberg DA, Curran TG, White FM. Early signaling dynamics of the epidermal growth factor receptor. Proc Natl Acad Sci U S A. 2016;113(11):3114-9.
Bagheri N, Shiina M, Lauffenburger DA, Korn WM. A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition. PLoS Comput Biol. 2011;7(2):e1001085.
Singh N, Basnet H, Wiltshire TD, Mohammad DH, Thompson JR, Héroux A, Botuyan MV, Yaffe MB, Couch FJ, Rosenfeld MG, Mer G. Dual recognition of phosphoserine and phosphotyrosine in histone variant H2A.X by DNA damage response protein MCPH1. Proc Natl Acad Sci U S A. 2012;109(36):14381-6.
Nguyen DN, Chen SC, Lu J, Goldberg M, Kim P, Sprague A, Novobrantseva T, Sherman J, Shulga-Morskaya S, de Fougerolles A, Chen J, Langer R, Anderson DG. Drug delivery-mediated control of RNA immunostimulation. Mol Ther. 2009;17(9):1555-62.
Reinhardt HC, Hasskamp P, Schmedding I, Morandell S, van Vugt MATM, Wang X, Linding R, Ong S-E, Weaver D, Carr SA, Yaffe MB. DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. Mol Cell. 2010;40(1):34-49.

Pages